Ken Griffin Tarsus Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$21.54 - $34.6 $170,166 - $273,340	7,900 Added 114.49%	14,800 $486,000
Q2 2024 Aug 14, 2024	SELL	$25.17 - $38.73 $130,884 - $201,395	-5,200 Reduced 42.98%	6,900 $187,000
Q1 2024 May 15, 2024	SELL	$19.61 - $39.22 $11,766 - $23,532	-600 Reduced 4.72%	12,100 $439,000
Q4 2023 Feb 14, 2024	BUY	$12.98 - $20.73 $10,384 - $16,584	800 Added 6.72%	12,700 $257,000
Q3 2023 Nov 14, 2023	BUY	$14.75 - $24.62 $135,700 - $226,504	9,200 Added 340.74%	11,900 $211,000
Q2 2023 Aug 14, 2023	BUY	$11.57 - $19.63 $25,454 - $43,186	2,200 Added 440.0%	2,700 $48,000
Q1 2023 May 15, 2023	SELL	$11.92 - $16.27 $463,688 - $632,903	-38,900 Reduced 98.73%	500 $6,000
Q4 2022 Feb 14, 2023	BUY	$14.12 - $18.72 $7,060 - $9,360	500 Added 1.29%	39,400 $577,000
Q3 2022 Nov 14, 2022	BUY	$14.08 - $18.5 $19,712 - $25,900	1,400 Added 3.73%	38,900 $666,000

170

43.3M

484K

4.1K

Ticker TARS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,658,500
Market Cap $1.41B
Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.